semaglutide type 1 diabetes automated insulin delivery randomized trial 2025 Use With in Adults With Diabetes: Qualitative Analyses and Patient-reported Outcomes From a Controlled ADA 2025 Recap: Improving Lives

In recent years, within the last ten years, several therapeutic drug managements (TDM) have been developed to manage DDIs (162)

4 reported observational data from Shanghai Sixth Peoples Hospital, China, showing that, with adequate treatment duration, GLP-1 agonists may have disease-modifying effects in patients with KOA with comorbid Type 2 diabetes, potentially mediated by weight loss

We are also grateful to PharmaNutra S.p.A, Pisa, Italy, for providing the Sucrosomial B12 used in this study

Common side effects include nausea (especially first dose), flushing, injectionsite reactions, and headache

Patient Consensus: Patients note that while some clinics only ask basic allergy questions, others require detailed medical records